BioNTech To Buy CureVac In $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech To Buy CureVac In $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on Above the Law.
The post BioNTech To Buy CureVac In $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on Above the Law.
